Search
Clinician Ordering Portal
Scientific evidence
Contribution of pharmacogenetic testing to modeled medication change recommendations in a long-term care population with polypharmacy
Dec 2016
Among long-term care facility residents, polypharmacy is common, and often appropriate, given the need to treat multiple, complex, chronic conditions. Polypharmacy has, however, been associated with increased healthcare costs, adverse drug events, and drug interactions. The current study evaluates the potential medication cost savings of adding personalized pharmacogenetic information to traditional medication management strategies.
Publication: Drugs Aging
An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi
Oct 2016
Establishes the performance of the gene expression signature in prospectively submitted cases with triple concordant diagnosis.
Publication: Cancer
The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists
Oct 2016
Definitive diagnoses by dermatopathologists in challenging melanocytic lesions increased by 57% by incorporating the results of 23-GEP.
Publication: Medicine
A tissue systems pathology assay for high-risk Barrett’s esophagus
Oct 2016
Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.
Publication: Cancer Epidemiology, Biomarkers & Prevention
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in class 1 and class 2 uveal melanomas
Jul 2016
We previously identified PRAME as a biomarker for metastatic risk in Class 1 uveal melanomas. In this study, we sought to define a threshold value for positive PRAME expression (PRAME+) in a large dataset, identify factors associated with PRAME expression, evaluate the prognostic value of PRAME in Class 2 uveal melanomas, and determine whether PRAME expression is associated with aberrant hypomethylation of the PRAME promoter.
Publication: Oncotarget
Individualized risk prediction in Barrett’s esophagus
Jul 2016
Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.
Publication: Medical Laboratory Observer
Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes
Jul 2016
Frequent mutations have been described in the following 5 genes in uveal melanoma (UM): BAP1, EIF1AX, GNA11, GNAQ, and SF3B1. Understanding the prognostic significance of these mutations could facilitate their use in precision medicine.
Publication: JAMA Ophthalmol
Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma
Jul 2016
Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk for metastasis.
Publication: JAMA Ophthalmol.
Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study
Jun 2016
Uveal melanoma management is challenging due to its metastatic propensity. DecisionDx-UM is a prospectively validated molecular test that interrogates primary tumor biology to provide objective information about metastatic potential that can be used in determining appropriate patient care. To evaluate the continued clinical validity and utility of DecisionDx-UM, beginning March 2010, 70 patients were enrolled in a prospective, multicenter, IRB-approved study to document patient management differences and clinical outcomes associated with low-risk Class 1 and high-risk Class 2 results indicated by DecisionDx-UM testing.
Publication: Journal of Oncology
A tissue systems pathology assay for high-risk Barrett’s esophagus
May 2016
Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.
Publication: Cancer Epidemiology, Biomarkers & Prevention
A tissue systems pathology test detects a field effect associated with high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts the presence of HGD and EAC in BE than pathologic variables and can improve histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego
Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients
May 2016
Post-test management plans were changed in 53% of patients who had risk aligned management changes concordant with a Class 1 (low risk) or Class 2 result (high risk).
Publication: Current Medical Research and Opinion